Outsourced Proportion Of Phase 2/3 Spend

By Industry Standard Research

ISR recently ran a survey to assess dynamics in the Phase 2/3 clinical development space. Survey respondents reported that, on average, two-thirds of their company’s spend on Phase 2/3 studies over the past year was outsourced. According to survey participants, large sponsors outsourced roughly half of their Phase 2/3 spend (55%), while midsize and small sponsors outsourced 73% and 80% of their spend, respectively.